Viridian Therapeutics Inc (VRDN)

Feb 21, 2025

Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Where are the Opportunities in (VRDN) - Stock Traders Daily

Feb 20, 2025

Feb 19, 2025

What Do Wall Street Analysts Think About Viridian Therapeutics Inc (NASDAQ: VRDN) Stock? - Stocks Register

Feb 19, 2025

Feb 19, 2025

Rice Hall James & Associates LLC Takes Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat

Feb 19, 2025

Feb 17, 2025

Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5%Should You Sell? - MarketBeat

Feb 17, 2025

Feb 12, 2025

Viridian Therapeutics Inc (NASDAQ: VRDN): Slumped -0.56% In 2025, Outlook Stable - Stocks Register

Feb 12, 2025

Feb 11, 2025

Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt? - Simply Wall St

Feb 11, 2025

Feb 10, 2025

Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Here's Why - MarketBeat

Feb 10, 2025

Feb 09, 2025

(VRDN) Trading Advice - Stock Traders Daily

Feb 09, 2025

Feb 07, 2025

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% – Should You Sell? - Armenian Reporter

Feb 07, 2025

Feb 07, 2025

VRDN Stock Sees Decline of Approximately -7.82% in Last Five Days - Knox Daily

Feb 07, 2025

Feb 06, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 06, 2025

Feb 06, 2025

Viridian's Strategic Expansion: 527,750 Share Options Awarded as TED Programs Advance - StockTitan

Feb 06, 2025

Feb 05, 2025

Analyzing Ratios: Viridian Therapeutics Inc (VRDN)’s Financial Story Unveiled - The Dwinnex

Feb 05, 2025

Feb 05, 2025

Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Feb 05, 2025

Feb 04, 2025

This trade activity should not be overlooked: Viridian Therapeutics Inc (VRDN) - SETE News

Feb 04, 2025

Feb 04, 2025

Wells Fargo Downgrades Viridian Therapeutics Inc (VRDN) to an Equal weight from an Overweight - Knox Daily

Feb 04, 2025

Feb 04, 2025

SG Americas Securities LLC Purchases 14,644 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat

Feb 04, 2025

Feb 03, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest - MarketBeat

Feb 03, 2025

Feb 03, 2025

Moody Aldrich Partners LLC Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat

Feb 03, 2025

Feb 02, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 02, 2025

Feb 01, 2025

Brokers Set Expectations for VRDN Q1 Earnings - MarketBeat

Feb 01, 2025

Feb 01, 2025

FY2029 Earnings Estimate for VRDN Issued By Leerink Partnrs - MarketBeat

Feb 01, 2025

Jan 31, 2025

SG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jan 31, 2025

Jan 30, 2025

Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN

Jan 30, 2025

Jan 30, 2025

Equities Analysts Offer Predictions for VRDN Q1 Earnings - Defense World

Jan 30, 2025

Jan 29, 2025

Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail

Jan 29, 2025

Jan 29, 2025

What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings? - Defense World

Jan 29, 2025

Jan 29, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Jan 29, 2025

Jan 29, 2025

(VRDN) Long Term Investment Analysis - Stock Traders Daily

Jan 29, 2025

Jan 22, 2025

Viridian Therapeutics sees stock soar after Phase III TED success - MSN

Jan 22, 2025

Jan 19, 2025

Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN

Jan 19, 2025

Jan 18, 2025

Viridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3%What's Next? - MarketBeat

Jan 18, 2025

Jan 14, 2025

JPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Jan 14, 2025

Jan 14, 2025

JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat

Jan 14, 2025

Jan 14, 2025

Sling Brings Potential Oral Competition To Amgen’s Tepezza In TED - News & Insights

Jan 14, 2025

Jan 09, 2025

Viridian Therapeutics (NASDAQ:VRDN) Earns “Buy” Rating from Needham & Company LLC - Defense World

Jan 09, 2025

Jan 08, 2025

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - BioSpace

Jan 08, 2025

Jan 08, 2025

Viridian Therapeutics, Inc. Promotes Seth Harmon to the Role of Chief Financial Officer - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

(VRDN) Investment Analysis - Stock Traders Daily

Jan 08, 2025